Phase 3 N=232 Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
Cancer · Pain
Primary: The Change of BFI-Bowel Function Index at visit8 — 48.3; 51.2 score on BFI
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=113 Effect of Infant Formula on Energy Balance
Development
Primary: Growth, Weight for Length (WLZ) Z Scores — -0.26; -0.12; -0.12; 0.13 Z score — p=<0.05
Phase 4 N=106 The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia.
Strabismus
Primary: Breath Duration — 2.14; 2.18; 2.26; 2.15 seconds
Phase 1 N=11 Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment
Diabetes Type I · Diabetes Type II
Primary: Percentage of Wound Area Reduction Compared to Baseline — 87 percentage of wound closure
Phase 2 N=31 Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
Pulmonary Arterial Hypertension
Primary: Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE) — 27 Participants
Phase 3 N=594 Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
Breast Cancer · Metastases
Primary: Overall Survival — 9.1; 9.3 Months — p=0.673
N/A N=319 Improving Health in Diabetes Project
Diabetes Mellitus
Primary: Diabetes Self-efficacy Measured Using the Diabetes Empowerment Scale Short Form (DES-SF)- Scores at Baseline — 3.66; 3.67 Units on a scale — p=0.05
Phase 4 N=15 QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in A1c — 9.74; 7.98 percent HbA1c — p=0.004
N/A N=263 Jump Start Shared Medical Appointments for Diabetes With Weight Management
Diabetes
Primary: Hemoglobin A1c — 8.2; 8.3 percentage of glycosylated hemoglobin
N/A N=86 Comparison of Repetitive Magnetic Stimulation and Exercise on Quadriceps Function in COPD
Chronic Obstructive Pulmonary Disease
Primary: Quadriceps Fibre Size of Type IIa Fibres — 3885; 4326; 3610 micrometers squared
N/A N=153 SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c
Diabetes Mellitus, Type 1
Primary: HbA1c at 6 Month — 8.47; 8.04 percentage of glycosylated hemoglobin — p=<0.0001
N/A N=47 Nasal Septal Flap for Donor Site Reconstruction
Nasal Septum Perforation
Primary: Mean Change in Post-operative Remucosalization at the Donor Site — 47.8; 37.8; 49.7; 43.5 percentage of remucosalization
Phase 1 N=40 A Safety Study of LY2886721 Single Doses in Healthy Subjects
Alzheimer's Disease
Primary: Number of Participants With Clinically Significant Effects (Adverse Events) — 0; 0; 0; 0 Participants
N/A N=1,601 The Patient-Reported Outcomes Project of HCV-TARGET
Hepatitis C, Chronic · Liver Diseases
Primary: Change in the Total Memorial Symptom Assessment Scale Mean Score (TMSAS) From Baseline to On-Treatment — -0.10; -0.1 units on a scale
N/A N=115 Heidelberg Edge Perimetry (HEP) Detecting Glaucomatous Visual Field Defects
Glaucoma
Primary: Correlation Coefficient Between HEP and OVF Mean Deviation (MD) — -.86; -.37 Pearson's correlation coefficient